Quantcast
Channel: Health Insurance Headlines on One News Page [United States]
Viewing all 22794 articles
Browse latest View live

PYA Named to IPA List of Top 200 Largest Accounting Firms

$
0
0
INSIDE Public Accounting has ranked national certified public accounting, management consulting, and healthcare advisory firm PYA at #103 on its list of the Top 200 2015 Largest Accounting Firms.

Knoxville, TN (PRWEB) September 23, 2015

PYA, a national certified public accounting and management consulting firm, is pleased to share it is again ranked as one of the “Top 200 Firms” as recognized annually by INSIDE Public Accounting (IPA). PYA has continued its ascent, climbing into the 103rd position—up from 107th in 2014—on the list of the 2015 Largest Accounting Firms.

Each year through its “Survey and Analysis of Firms,” IPA gathers and compiles in-depth financial and operational data from more than 500 accounting firms across North America. From this data IPA publishes a ranking, by net revenues, of the Top 200 Largest Accounting Firms. According to IPA, this list is the most comprehensive published list of the 101st to 200th largest accounting firms.

“We are honored to be recognized among the nation’s leading accounting firms,” said PYA CEO Ed Pershing. “For more than 30 years, PYA’s foundation has been and will continue to be built on a culture of help. Even though our quality standard supersedes goals singularly related to size, this ranking demonstrates PYA’s effective response to the growing needs of our clients and industries that we serve. It is also a testament to the hard work, cooperation, and unwavering commitment made by our entire team to supporting the needs of our clients.”

In addition to this award, PYA was recently ranked by Modern Healthcare as the nation’s ninth largest privately held healthcare consulting firm. For more information, visit http://www.pyapc.com/.

-------------
About PYA
For over three decades, Pershing Yoakley & Associates (PYA), a national professional services firm providing management consulting and accounting has helped its clients navigate and derive value amid complex challenges related to regulatory compliance, mergers and acquisitions, governance, business valuations and fair market value assessments, multi-unit business and clinical integrations, best practices, tax and assurance, business analysis, and operations optimization.

Founded in 1983, PYA’s steadfast commitment to an unwavering client-centric culture has served the firm’s clients well. PYA is now ranked by Modern Healthcare as the 9th largest privately owned healthcare consulting firm in the US. PYA is also ranked 103rd by INSIDE Public Accounting’s “Top 200” Largest Accounting Firms. PYA affiliate companies offer clients world-class data analytics, professional real estate development and advisory resources, self-insured employer health insurance claims audits for Fortune 500 companies, wealth management and retirement plan administration, and business transitions consulting.

PYA is headquartered in Knoxville, Tennessee. For more information, please visit http://www.pyapc.com/ Reported by PRWeb 14 hours ago.

Antitrust Concerns come in the Way of Mergers in the Health Insurance Industry

$
0
0
Aetna-CEO-Mark-T-Bertolini.jpg

Aetna and Humana, the two big health insurers have proposed a merger but the U.S. Justice Department is not yet convinced and asked for more information related to the proposal from the companies for the $37 billion merger.

read more Reported by TopNews 14 hours ago.

Zynex, Inc. Announces FDA Filing for Blood Volume Monitor

$
0
0
510(k) application filed for CM1500 with the Food and Drug Administration.

Lone Tree, Colorado (PRWEB) September 23, 2015

Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac and neurological diagnostics, and compound pharmacy, announced today that its wholly-owned subsidiary, Zynex Monitoring Solutions Inc., has filed an application with the Food and Drug Administration pursuant to Section 510(k) of the Food, Drug and Cosmetic Act for clearance of its new CM1500 monitoring device. The CM1500 is capable of monitoring a patient’s fluid levels, including blood loss, during surgery and in recovery.

Thomas Sandgaard, Zynex CEO stated: “We are excited to have reached the point of applying for FDA clearance for our revolutionary device that will enable surgical personnel to non-invasively monitor blood loss in real time. We have begun placing initial production units in hospitals for field testing and validation.” Sandgaard went on to say “Undetected blood loss continues to be a significant risk during surgery and recovery, and current approaches are either too invasive or lacking precision and early predictive capability for blood loss and intervention. The CM1500 will reduce the risk of blood loss going undetected.”

About Zynex
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex’s product lines are fully developed, FDA-cleared and commercially sold world-wide. Zynex also operates a non-sterile compound pharmacy providing topical and transdermal pain creams. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.

For additional information, please visit: http://www.zynex.com

Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2014.

Contact: Zynex, Inc. 303-703-4906 Reported by PRWeb 10 hours ago.

Inadequate controls found in N.Y. health insurance exchange

$
0
0
The inspector general for the US Department of Health and Human Services has found shortcoming in the controls that New York' -More-  Reported by SmartBrief 9 hours ago.

So you think you know health insurance, eh?

$
0
0
LOUISVILLE, Ky., Sept. 23, 2015 /PRNewswire-USNewswire/ -- Let a member of the nonprofit Kentucky Health Cooperative's Education and Outreach team make your next meeting even more worthwhile. The organization's Health Insurance Literacy specialists makes presentations to clubs,... Reported by PR Newswire 9 hours ago.

New Mexico Health Connections, New Mexico’s Non-Profit, Consumer Operated and Oriented (CO-OP) Health Plan, Selects Qualmetrix, Inc. as Its Healthcare Analytics Partner

$
0
0
New Mexico Health Connections, New Mexico’s Non-Profit, Consumer Operated and Oriented (CO-OP) Health Plan, Selects Qualmetrix, Inc. as Its Healthcare Analytics Partner MIRAMAR, Fla.--(BUSINESS WIRE)--QualMetrix, a healthcare analytics company delivering actionable insights to payors, providers and employers to help them reduce cost while enhancing the quality of healthcare, has been selected by New Mexico Health Connections as its healthcare analytics partner. New Mexico Health Connections is a consumer operated and oriented (CO-OP) health plan available on both the individual and small business health insurance exchanges and through the commercial marketplac Reported by Business Wire 9 hours ago.

Blue Cross and Blue Shield of Kansas City Announces Medicare Advantage Plan

$
0
0
Lumeris’ solutions will help insurer operate a new value-based offering to seniors

Kansas City, MO (PRWEB) September 23, 2015

Blue Cross and Blue Shield of Kansas City (Blue KC), the largest not-for-profit health insurer in Missouri, is entering the Medicare Advantage market in 2015 with Blue Medicare Advantage plans available in nine counties in Kansas and Missouri (Cass, Clay, Clinton, Jackson, Lafayette, Platte, and Ray in Missouri, Johnson and Wyandotte in Kansas). Blue KC will offer two Medicare Advantage HMO plan options based on financial preferences and healthcare needs.

“Blue KC has been a trusted health insurance leader in Kansas City for more than 75 years and we are excited to offer Blue Medicare Advantage plans (designed by and for Kansas Citians),” said Danette Wilson, president and CEO of Blue KC. “We’ve put our years of local knowledge to work building affordable Medicare Advantage plans that will meet the needs of our community.”

To assist with its entrance into the Medicare Advantage space, Blue KC will partner with Lumeris, a pioneer in population health management solutions. With its near decade of experience in operating Essence Healthcare, a 4.5-Star rated Medicare Advantage Prescription Drug (MAPD) plan, Lumeris will help Blue KC establish a robust business model based on an integrated population health platform. Data collected will help physicians partner with patients in their care and the platform will interact with members to provide reminders, alerts, coaching advice and treatment information.

“We are pleased that Blue KC has partnered with Lumeris to design and manage an outcome-based health plan,” said Richard Jones, president and CEO of Essence Healthcare. “We are eager to take what we have learned from our 4.5-Star rated plan to position Blue KC for success.”

Blue KC has been leading the way for its members to experience improved healthcare delivery through a coordinated care model it launched in 2009. With Blue Medicare Advantage, Blue KC is taking this approach to the next level, emphasizing its belief in a strong doctor-patient relationship that delivers proactive, effective and convenient care.

“Lumeris provides the proven processes and services that Blue KC needs to effectively manage and maintain the best-in-market Medicare Advantage plans,” said Wilson. “Our partnership with Lumeris will enable us to achieve our goals of transforming healthcare delivery in Kansas City to value-based care models, and offering better outcomes to the area’s Medicare eligible.”

With assistance from Lumeris to improve care coordination, Blue KC will be in a position to meet the industry’s goals of the Triple Aim plus One: improved quality, cost, and patient plus physician satisfaction.

“By leveraging our experience and proven systems, we will actively partner with Blue KC to lower the cost of healthcare and increase operational efficiencies,” said Michael Long, chairman and CEO of Lumeris. “Our value-based health plan solutions will also position Blue KC membership to experience improved care coordination and quality of care.”

Blue Medicare Advantage plan details will be released on October 1, 2015.

Blue Cross and Blue Shield of Kansas City’s Blue Medicare Advantage is an HMO plan with a Medicare contract. Enrollment in Blue Medicare Advantage depends on contract renewal.

ABOUT BLUE CROSS AND BLUE SHIELD OF KANSAS CITY
Blue Cross and Blue Shield of Kansas City, the largest not-for-profit health insurer in Missouri and the only not-for-profit commercial health insurer in Kansas City, has been part of the Kansas City community since 1938. Blue Cross and Blue Shield of Kansas City provides health coverage services to more than one million residents in the greater Kansas City area, including Johnson and Wyandotte counties in Kansas and 30 counties in Northwest Missouri. Our mission: to use our role as the area's leading health insurer to provide affordable access to health care and to improve the health and wellness of our members. Blue Cross and Blue Shield of Kansas City is an independent licensee of the Blue Cross and Blue Shield Association. For more information on the company, visit its website at BlueKC.com.

ABOUT LUMERIS
Lumeris is a pioneer in population health management solutions. Through our operations, technology and consulting services, we enable healthcare organizations to successfully make the journey from volume- to value-based care. We help health systems create Population Health Services Organizations and define populations for risk. We empower providers and their accountable care teams with process improvement strategies, technology tools and clinical workflows to manage their patients and populations effectively. We work collaboratively with payers to ensure the right contracts, measures and incentives are in place to influence physician behavior and drive quality, cost and utilization performance. The depth and breadth of Lumeris’ solutions – combined with its decade of experience in value-based care – make the company an ideal partner for any healthcare organization seeking to transform its business and care-delivery model and remarkably improve its clinical and financial outcomes. For more information, call 1.888.586.3747 or visit Lumeris.com.

### Reported by PRWeb 8 hours ago.

Oscar And The Changing Health Insurance Landscape

$
0
0
Yesterday, the Senate Judiciary Committee’s Subcommittee on Antitrust, Competition Policy and Consumer Rights held a hearing on “Examining Consolidation in the Health Insurance Industry and Its Impact on Consumers,” at which the CEOs of Anthem and Aetna testified.  Both of these health insurers have announced friendly take-overs of two other [...] Reported by Forbes.com 5 hours ago.

It's really hard to like a lot of health-insurance options right now.

$
0
0
Eric Trump, controller at Steve Reiff, as quoted by The Associated Press -More-  Reported by SmartBrief 5 hours ago.

How Clinton Wants To Turn Obamacare Into Hillarycare 2.0

$
0
0
WASHINGTON -- Hillary Clinton wants to tackle one of the biggest items of unfinished business in health care reform by offering policy proposals she says will help patients with high and rising out-of-pocket costs.

In a summary of those plans issued Wednesday, Clinton's campaign vows to preserve the Affordable Care Act while adding new benefits like a tax credit for households with the highest out-of-pocket costs and protections against surprise medical bills.

Clinton previewed her health care proposals on Tuesday during an event in Des Moines, Iowa, that was mostly focused on her policies seeking to reduce prescription drug costs.

"I will defend the Affordable Care Act, but as president I want to go further," Clinton said. "I want to strengthen the Affordable Care Act, because the truth is, it couldn't and it didn't solve all of our problems."

By both backing President Barack Obama's most significant domestic policy achievement while also acknowledging its shortcomings and pledging to improve it, Clinton is, in a way, returning to her roots and reclaiming ownership of a signature issue.

Health care reform helped define Clinton in the 1990s when she headed former President Bill Clinton's failed efforts to make over the system into what critics in the insurance industry and the Republican Congress derided as "Hillarycare." During the 2008 Democratic primary, Clinton and Obama sparred over their competing health care platforms, and while Obama won the nomination, he ultimately embraced the individual mandate to get health coverage that was the cornerstone of Clinton's plan. And while representing New York in the Senate in 2009, Clinton played a small, early role in developing when became the Affordable Care Act before departing Congress to join Obama's cabinet as secretary of state.The Obama administration has cited successes of the law, including extending health coverage to an estimated 17.6 million previously uninsured people since 2013, and overseen a historic slowdown in the speed on health care spending growth. But out-of-pocket costs like high deductibles and big copayments are becoming increasingly common in both job-based health plans and those bought on the Obamacare exchanges, and can squeeze household budgets and make health insurance itself seem less valuable. "Yes, the uninsured rate is the lowest in decades, but the cost of prescription drugs went up by over 12 percent last year. Your income, I'd bet, didn't go up 12 percent," Clinton said Tuesday. "Meanwhile, other out-of-pocket costs are growing, too, and the insurance companies just keep raising the premiums. So while the overall growth in health care spending has slowed -- and that's good news for our economy -- for a lot of families, it doesn't feel like health care costs are coming under control." A linchpin of Clinton's plan is a tax credit worth up to $5,000 that would be made available to households with out-of-pocket health care costs that exceed 5 percent of their income in a year, which she would finance by cutting federal spending on prescription drugs. To make high-deductible insurance more useful to consumers with modest health care needs, Clinton proposes requiring insurers to cover three doctor visits a year outside the deductible.

Clinton also calls for new rules that would protect patients against unexpected bills incurred during a medical emergency when a provider at the hospital isn't in the patient's insurance network even though the hospital itself is. Other elements of her plan include promising better and more up-to-date information about what health care providers and prescription drugs are covered by insurers, increased federal authority to block large health insurance premium hikes and stricter oversight of mergers between health care companies.

Clinton's pitch, however, fails to address some contentious Obamacare issues currently under debate in Congress -- and not just among those who want to repeal the law.

Large employers and labor unions have attracted bipartisan support for doing away with, or at least scaling back, the Affordable Care Act's so-called Cadillac tax on the highest-cost health insurance plans. This tax helps pay for Obamacare and is key to the law's efforts to reduce health care costs by curtailing generous health insurance that encourage heavy use of the medical system. But critics are concerned the levy will hit more consumers than Congress envisioned, and cause employers to significantly scale back their health benefits to avoid it. Clinton expressed sympathy with these concerns to the Des Moines Register editorial board on Tuesday, but said replacing the money it raises would be difficult, Politico reported.

Clinton also didn't address the law's looming redefinition of small employers, which may raise health insurance premiums for companies with younger, healthier workforces even as it lowers rates for firms with older, sicker employees. Delaying or undoing this rule also has attracted support from Democrats who otherwise support Obamacare.

Using the Affordable Care Act as the foundation for her health care proposals sets Clinton apart from her rival for the Democratic nomination, Sen. Bernie Sanders (I-Vt.). Although Sanders voted to enact the law in 2010 and has not wavered in his support for its achievements, he is an outspoken advocate for replacing the current health care system with a single-payer program akin to those in most other rich nations.

Clinton also is taking aim at the Republican presidential field and their counterparts in Congress, who remain steadfastly committed -- rhetorically, at least -- to undoing Obamacare more than five years after it became law.

"Apparently, they're going to keep voting to repeal it," Clinton said Tuesday. "It doesn't matter what the facts are, they are partisan ideologues and they're going to keep trying to tear it up and force us back into a debate about health care. Well, politics can be, unfortunately, a pretty cynical business but this really goes further than I can tolerate."

*Jonathan Cohn contributed reporting.*

-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. Reported by Huffington Post 4 hours ago.

Clinton Plan Aims to Limit Cost of Health Insurance

$
0
0
Hillary Clinton released more proposals for limiting what people with insurance pay for their health care, amid an effort to show she is seeking to improve the 2010 federal health law with cost provisions. Reported by Wall Street Journal 4 hours ago.

Long Island Medical Marijuana Doctor Is Ready To Start Seeing Patients

$
0
0
Dr. Kevin Custis joins the Medical Cannabis Network to start seeing Long Island patients for the New York Medical Marijuana Program.

Long Island, New York (PRWEB) September 23, 2015

Long Island residents seeking medical marijuana treatment for their condition can now see a doctor located out of Brooklyn to begin a bona fide relationship for the New York cannabis program. Marijuana Doctors.com has started to work with local physicians and patients around Long Island who are looking to qualify based on the state’s criteria. Marijuana Doctors received over 12,000 registered patients from New York looking to participate in the program since the beginning of January this year. With this foresight, Marijuana Doctors.com is able to provide the resources for patients in the case that a patient’s primary doctor refuses to consider medical marijuana as a viable treatment option.

Dr. Kevin T. Custis, M.D. is one of the first doctors to join the Medical Cannabis Network in New York. Dr. Custis is a primary care physician and part time Professor at SUNY Downstate Medical School in the Department of Family Medicine. Dr. Custis has been in practice for over 19 years serving the Long Island and New York City community at his medical office. Having grown up in the inner-city area of Baltimore, Maryland he is extremely committed to providing compassionate primary care in an urban setting. The affordable initial visiting fee is $95, for patients mentioning MarijuanaDoctors.com, if the patient does not have an accepted health insurance plan.

In early June, Dr. Custis attended the 8 hour medical cannabis educational course hosted by Marijuana Doctors at the International Cannabis Association Expo held at the Javits Center. Dr. Custis is a physician, who understands the medical benefits of marijuana and unlike most doctors in New York, is willing to provide medical marijuana evaluations for eligible patients, with a majority who has exhausted conventional methods of medicine. Despite not having the patient or doctor registry up and running for the state of New York, Dr. Custis is serving the high demand from patients, who want to candidly and discreetly discuss the option of medical cannabis with a knowledgeable doctor. Dr Custis cannot write a medical cannabis recommendation as per state standards yet, but he is willing to start the relationship with each patient so that he can better understand his or her medical history and if medical cannabis would be a good option.

Since the passing of the New York Compassionate Care Act, signed into law by Gov. Cuomo on July 5th 2014, Marijuana Doctors has taken incredible strides in creating a turnkey solution for physicians. The medical marijuana platform created, allows doctors to stay within the guidelines of state laws, remain HIPPA compliant, as well as offering a comprehensive reporting system. Doctors can create the medical record for the patient using the MD software, while showing a continuous relationship as the patient is placed on a medical cannabis treatment plan.

Patients, after leaving the doctor’s office can utilize the Marijuana Doctors patient application to report the effects cannabis have back to the doctor who enrolled the patient into the state program. “We wanted to show how a doctor can monitor the patient’s health even after they leave the doctor’s office since there is so much we still don’t know about cannabis, our app does just that,” said COO John Nicolazzo. The medical patient’s app allows patients to record the effects of the product they purchased from a local New York marijuana dispensary and simply report the results to the doctor for review. If the patients have a negative effect recorded in the app after ingesting cannabis, then an alert will be sent to the doctors recommending to the treating physicians that an adjustment in the treatment plan might need to take place. The development of this platform has cost Marijuana Doctors close to 3 Million dollars to date since its inception back in 2009.

Marijuana Doctors is owned and operated by the Medical Cannabis Network. Established in 2009, the Medical Cannabis Network has been a leader in the cannabis industry of all things related to education, advertising, compliance, business startups and regulatory matters. With over 1200 owned marijuana related domains, MCN has developed over 300 websites in this sector. 20 of the 300 domains are established business models intended to educate both the consumer and businesses looking to involve themselves further. For more information on how to get involved in the medical cannabis or recreational cannabis industry, please see contact person on right side. Reported by PRWeb 4 hours ago.

Survey of private health insurance plans finds large increase in deductibles since 2010

$
0
0
There's a reason consumers feel like they are spending more money on health care. Reported by dailypress.com 2 hours ago.

The FDA and Regulation of Homeopathic Medicines

$
0
0
The U.S. Food and Drug Administration (FDA) is presently re-evaluating regulation of homeopathic medicines (1). Below is excerpt of the testimony provided to the FDA by Dana Ullman, MPH, CCH:

*SUMMARY*

Before addressing the specific questions that the Food and Drug Administration (FDA) poses in the Federal Register notice announcing a public hearing on the regulation of homeopathic medicines, it is first important to address the areas of special interest that seem to have led to the hearings (references will not be provided in this summary, only in the primary part of this testimony):1. The FDA asserts that the homeopathic industry has grown substantially, and it quotes a National Health Interview Survey, conducted by the Centers for Disease Control and Prevention's National Center for Health Statistics in 2007, that estimated that adults spent about 2.9 billion on the purchase of homeopathic medicine. The information provided below will show that the sales and popularity of homeopathic medicine has grown each decade since the 1970s, the government's figures are inflated substantially, are not accurate figures of the sales of homeopathic medicines in the United States, and seems to include sales of many non-homeopathic products.3. The FDA announcement about this hearing also asserted, "The 2012 American Association of Poison Control Center Annual Report indicated that there were 10,311 reported poison exposure cases related to 'Homeopathic Agents.'" However, no evidence was provided that these numbers were accurate, and in fact, there is some compelling evidence to suggest that they are not accurate due to the ambiguous nature of the category "Homeopathic Agents" which evidence suggests includes significant amounts of "non-homeopathic" products.5. Several of the presentations made at the FDA hearing (April 20-21, 2015) asserted that there is "no evidence" that homeopathic medicines are effective for any condition. The information provided below will show this statement is not true. Studies demonstrating the effectiveness of homeopathic medicines have been published in leading medical journals, including the *Lancet*, *BMJ*, *Chest* (the publication of the American College of Chest Physicians), *Rheumatology* (the publication of the British Society for Rheumatology), *Pediatrics* (publication of the American Academy of Pediatrics), *Cancer* (journal of the American Cancer Society), *Pediatrics Infectious Disease Journal* (publication of the European Society of Pediatric Infectious Diseases), *European Journal of Pediatrics* (publication of the Swiss Society of Pediatrics and the Belgium Society of Pediatrics), and numerous others. Some researchers have chosen to create arbitrary guidelines that claim that no study is "reliable" unless it has greater than 150 subjects, No peer-review journal and independent research organization has ever claimed that these guidelines for determining "reliability" on research are valid or even reasonable.7. Who uses homeopathic medicines? Every (!) survey conducted to date has had numerous findings, but the one consistent finding is that people who use homeopathic medicines tend to be more educated than those who do not. The question about "who uses homeopathic medicines" is important to policymakers who are seriously interested in honoring American citizens and their right to make personal health decisions that impact themselves and their families.
*Opening Comments *

Homeopathy and advocates for this system of medicine have had a long-time collaborative relationship with the F.D.A. ever since this health agency was first empowered with regulatory controls as a result of the famed Federal Food Drugs and Cosmetics Act of 1938. The primary author of this important consumer protection law was the three-time Senator from New York, Royal Copeland, who was not only a medical doctor, he was a homeopathic physician and ophthalmologist. Besides empowering the FDA with considerable regulatory powers, this law also gave federal recognition to the Homeopathic Pharmacopeia as a compendium of drugs. Even though other parts of the "natural health movement" have not had a collaborative relationship with the F.D.A. in the 20th and 21st centuries, evidence of the homeopaths' good working relationship with the F.D.A. is even in evidence today by the non-combative and collaborative presentations by representatives of different constituencies of the homeopathic community at the F.D.A.'s hearings on April 20-21, 2015.

The intent of this testimony is to help improve consumer protections through Good Manufacturing Practices of homeopathic medicines while at the same time trying to maintain reasonable and optimal freedom to access safe medicines for individual and family health. There may be only a relatively small percentage of Americans who utilize homeopathic medicines, but there is strong evidence that the people who use these natural medicines are more educated than those who do not, and further, these medicines play an important and practical role as a safer alternative to pregnant and lactating women as well as to parents who wish to treat their infants and children with safer medications.

The most famous dictum from Hippocrates, the Father of Medicine, has been his wise words that he meant for physicians but ultimately is also wise advice for everyone, when he asserted, "First, do no harm."

There may be different opinions about the efficacy of homeopathic medicines, and yet, according to the World Health Organization, there is general consensus from advocates and skeptics alike that these medicines are basically safe(2). Some skeptics of homeopathy may assert that the usage of homeopathic medicines may delay the use of supposedly effective conventional drugs; however, there are generally even greater and more frequent risks, in addition to a staggering $750 billion in wasteful healthcare spending, when people receive conventional medical care (3). When assessing the risks of delayed medical care, one must also acknowledge the much greater risks that result in getting conventional medical care immediately especially due to the dangers of many medical treatments, let alone due to the common and inadequately studied usage of multiple drugs concurrently.

Before discussing safety and efficacy issues, it is important to know something about the international context for homeopathy and the historical context for homeopathy. By better understanding these issues, health policy advisers and legislators can learn what does and doesn't work in one country or another and in the past, present, and future.

For instance, a recent survey of French physicians found that 95% of general practitioners, pediatricians, and dermatologists prescribe homeopathic medicines (4). When you consider that the World Health Organization recently ranked countries for having the best (or worst) health care system in the world, France was ranked number 1 (5).

According to a 2010 article in the *BMJ *(British Medical Journal), an impressive 57% of people in Germany use homeopathic medicines (6). The *BMJ* recently reported that when German politicians recently sought to stop government reimbursement for homeopathic treatment, the German Medical Association has announced its support for homeopathy and for reimbursement for homeopathic care. Further, the association's president, Jörg-Dietrich Hoppe, defended homoeopathic treatment in an official statement. He said that homeopathy was an important part of medicine.

Starting in 2007, the prestigious European Science and Technology Observatory started to monitor the attitude of Italians towards homeopathy. In 2007 they found that 32.5% of Italians at least occasionally used homeopathic medicines. In 2009, they found that this number grew considerably to 38.6% (7).

Although these numbers for the use of homeopathic medicines in Europe may be substantial, the numbers are even more significant in India, where there are 300,000 qualified homeopaths, 180 homeopathic medical schools, 7,500 government clinics, 307 hospitals and 24 State Boards for the registration of qualified practitioners of homeopathy. Acknowledging the widespread popularity of homeopathy, a World Health Organization publication noted that "in the Indian subcontinent the legal position of the practitioners of homeopathy has been elevated to a professional level similar to that of a medical practitioner."

According to the *Lancet*, about 10% of the population of India, approximately 100 million people, depend SOLELY on homeopathy for their health care (8). According to an AC Nielsen survey in India, 62% of current homeopathy users have never tried conventional medicines, and 82% of homeopathy users would not switch to conventional treatments. When you consider that 100 million people (!) are using homeopathic medicines for ALL of their health care needs and when you consider that they are using these natural medicines for mild and serious infections, for minor and significant pain syndromes, for various stages of cancer and heart disease, and for various types and degrees of mental illness, it is remarkable that anyone today would still consider these medicines as "placebos" (I personally challenge any single MD to prescribe only placebos to their patients for just one week for them to realize that their patients are not getting better and will seek health care from other providers).

A small but vocal group of skeptics of homeopathy persist today. These skeptics theorize that homeopathy simply doesn't make sense to them and that it "cannot possibly work." The fact of the matter is that there is compelling evidence published in highly respected scientific journals, such as *Langmuir* (a journal published by the American Chemistry Society), that shows that three types of spectroscopy have confirmed that nanodoses of six different homeopathic medicines persist in solution and in doses similar to the nanodoses in which many of our hormones and cell signaling agents operate, even after these medicines have undergone six, 30 or even 200 dilutions of 1:100 (9).

Despite high quality research that verifies that nanodoses persist, this small but vocal group of skeptics continues to misinform others by asserting that "there is nothing in homeopathic medicines." Such assertions also fly in the face of the majority of meta-analyses that have been conducted as well as the variety of clinical trials and basic sciences studies, and equally important, such assertions seem to ignore real-life medical care that utilizes homeopathic medicine regularly for a wide variety of acute care, chronic disease management, and emergency medical services,

In the light of the fact that homeopathy is so widely used throughout the world and in light of the fact that it is particularly appreciated by educated populations, it is recommended that the FDA be mindful when considering new regulations that may reduce the availability of homeopathic medicines unless there is clear and obvious evidence of safety issues involved in their usage.*More Accurate Evidence for the Sales of Homeopathic Medicines in the USA (1990 to Present)*

The field of homeopathic medicine has had a long, good working relationship with the FDA since the passing of the Federal Food Drug and Cosmetic Act of 1938. The current investigation to determine whether FDA should revise the Compliance Policy Guide that governs homeopathy is based, in part, on the supposed growth in the sales of homeopathic medicine to $2.9 billion. However, one can and must question the accuracy this figure because this figure estimated the number of American using homeopathic medicines in the USA as around 3.3 million (seemingly accurate) but that these Americans supposedly made 69.3 million purchases of homeopathic medicines (questionably accurate).

Although this same report asserts that the "Number of purchases per person" were 1.58, the "Total number of purchases per year" suggests that these people made almost 21 purchases per month. Therefore, the $2.9 billion figure seems to be inflated by a 13-fold factor. This report estimates that the average purchasers of "Nonvitamin, nonmineral, natural products" purchases around 18 such products per year. It is therefore clearly inaccurate that Americans purchase more homeopathic medicines per person than nutritional products, especially when it is quite common for homeopathic practitioners and homeopathic books to recommend only ONE medicine at a time.

Based on the above information and based on other evidence about the sales of homeopathic medicines over the past several decades (described below), one must question the accuracy of the total number of purchases of homeopathic medicines as well as the overall cost of these medicines.

Below is a summary of previous surveys about the sales and usage of homeopathic medicines in the U.S. Unless the sales and usage of homeopathy truly exploded in the past couple of years, it is highly unlikely, perhaps impossible, that homeopathic sales are truly $2.9 billion in the U.S.

In the 1990s homeopathic industry grew up to $250 million per year in sales, with an annual growth rate of 20-25% (10). Although the size of this industry is relatively small by most American standards, its growth rate is considered significant but is still considered extremely small in relation to the overall sales of drugs in the USA which is estimated to be around $260 billion.

In 2004, the *Los Angeles Times* estimated that the homeopathic market in the U.S. was $400 million and its market growth was described as "strong" (11). In June, 2007, the Natural Food Merchandiser estimated homeopathic sales in "natural products stores" to be $272 million, an 11.3% increase from the previous year.

A one-year survey ending December 1, 2007, found that sales of homeopathic medicines in conventional food and markets increased 19% and in natural foods supermarkets by 35%.

Based on ALL of the above surveys, it is highly unlikely that the sales of homeopathic medicines somehow increased by a 300% to 400% in a couple of years. Most likely, the survey mixed data from herbal/botanical sales with those of homeopathic medicines.*Questionable Accuracy of Poison Exposure Cases Related to "Homeopathic Agents"*

The FDA announcement about this hearing also asserted, "The 2012 American Association of Poison Control Center Annual Report indicated that there were 10,311 reported poison exposure cases related to 'Homeopathic Agents,' with 8,788 of those reported cases attributed to children 5 years of age and younger. Of the 10,311 reported cases, 697 required treatment in a health care facility." It should be acknowledged that a lot of consumers are confused by the term "homeopathic," and they commonly mis-assume that herbal remedies and other types of supplements are "homeopathic" when this is not the case. Further, this Report provides no assurance that any legally defined homeopathic drug was included in the term "Homeopathic Agents." The term, "Homeopathic Agents," is not used by consumers or clinicians, and it may have become a generic category for whatever the consumer or the survey giver guessed as the proper category. More importantly, poison control data only reflects the fact that a person, usually a parent, called a poison control center and asked a question about an agent. The call from a parent who was told not to worry has the same statistical weight as a parent who was told to take their child to the emergency room.

The bottom line is that this Report provided absolutely no clarity or assurance that its reporting on "homeopathic drugs" was accurate. Further, given the relatively high number of incidences, the authors of this Report chose to not breakdown the 9,704 into specific drugs and this lack of specificity suggests that this category was used as some type of "garbage can" category than as a real category relating to "homeopathic drugs".

Although it seems highly unlikely that the term "Homeopathic Agents" was meant to only include "homeopathic drugs," the good news is that there was only one death and a total of only three "major" outcome problems.

Additional evidence that the above concerns are real is provided in the 2010 American Association of Poison Control Center Annual Report, where on page 150 a case is described in which a "self-claimed homeopath" prescribed 2 tablespoons of 32% hydrogen peroxide for his wife. Needless to say, hydrogen peroxide is not a homeopathic drug.

It should also be noted that these reports from the Poison Control Center generally provide specifics and details about each poisoning, breaking down each poisoning from each botanical product, amino acid supplement, or "cultural" medicine (i.e. Asian medicines, Ayurvedic medicines, Hispanic medicines, etc). However, the category of "Homeopathic Agent" is not broken down, and therefore, there is no clear or solid evidence that any of the experiences were actually from homeopathic drugs.

It should also be noted that in reviewing the number of "deaths" reported from "Homeopathic Agents" in the years 2010 to 2013, two years (2011 and 2013) report no deaths, one year reports one death though the case is described as a husband giving his wife Hydrogen peroxide (2010), and one year reported one death without providing any details (2012). The number of "Major" outcome problems each year from 2010 to 2013 was, in order, 2, 4, 3, and 1, suggesting that whatever problems "Homeopathic Agents" caused were very rarely "major."*More Accurate Information on Scientific Evidence for Clinical Efficacy of Homeopathic Medicines*

Two presentations at the FDA hearings (Michael De Dora, Center for Inquiry; Adriane Fugh-Berman, MD, Georgetown University) quoted a recent report on homeopathy conducted by the Australian government, asserting, "There are no health conditions for which there is reliable evidence that homeopathy is effective." However, neither of these presentations discussed what was meant by "reliable evidence that homeopathy is effective."

This Australian government report acknowledged a significant body of scientific evidence that homeopathic medicines are effective for a wide number of acute and chronic ailments, and it provided references to these studies that verify this efficacy and that were published in some of the most respected medical journals in the world, including: *Lancet, BMJ, Chest* (the publication of the American College of Chest Physicians), *Rheumatology* (the publication of the British Society for Rheumatology), *Pediatrics* (publication of the American Academy of Pediatrics), Cancer (journal of the American Cancer Society), *Pediatrics Infectious Disease Journal *(publication of the European Society of Pediatric Infectious Diseases), *European Journal of Pediatrics* (publication of the Swiss Society of Pediatrics and the Belgium Society of Pediatrics), *British Journal of Pharmacology*, and numerous others. Further, all of the above studies were randomized, double-blind, and placebo controlled.

However, the authors of the Australian report chose to create an arbitrary determination that studies of less than 150 subjects were deemed "too small" to be considered "reliable." Although there are numerous studies published in the above journals that have shown that homeopathic medicines provide therapeutic benefit beyond that of a placebo and that have had over 150 subjects in them, the Australian government's report created an additional arbitrary determination that unless there were THREE independently conducted trials each with 150 subjects that such evidence would be considered "unreliable" (12). The adoption of highly restrictive and somewhat arbitrary criteria must be acknowledged in any good faith discussion of this study. However, surprisingly, this information was omitted by the summary abstracts of this report and in every major media discussion of this report.

It should be emphasized that based on the above arbitrary guidelines for what these authors deem to be "reliable" that acupuncture or virtually every botanical remedy would be deemed to be "useless,""unproven," and "unreliable."

Further, when the *British Medical Journal*'s "Clinical Evidence" analyzed common medical treatments to evaluate which are supported by sufficient reliable evidence (13), they reviewed approximately 3,000 treatments and found only 11% were found to be beneficial. It should be noted and emphasized that the *British Medical Journal* deemed 20 subjects to be a more reasonable guideline (14).

If the Australian government used the British Medical Journal's guidelines, the results of their study would have been dramatically different. Even the Cochrane Community, the highly respected non-commercial group of researchers who evaluate research, does not ignore studies smaller than 150 subjects.

One final statement about this Australian government report needs to be made. The private research group which wrote this report for the Australian government, Optum, referenced a *BMJ* article for why it deemed 150 subjects to be the "minimum" necessary for any and every study to be "reliable" (15). In fact, this article specifically warns against using its criteria for evaluating different kinds of studies: "because our results were based on meta-analyses of trials assessing binary outcomes, they cannot be extrapolated to trials assessing continuous outcomes because such trials usually differ in medical condition, risk of bias, sample size, and statistical analysis." Because a significant amount of homeopathic research is based on continuous outcomes, the authors of the Australian government's report ignored this crucial warning.

Some of the studies ignored by the authors of the Australian report are instructive. Jennifer Jacobs, MD, MPH (University of Washington) and her team conducted three studies on childhood diarrhea (randomized double-blind and placebo controlled trials totaling 242 children), a condition that the World Health Organization deems to be one of the most serious public health problems in the world due to the millions of deaths in children from dehydration. Jacobs used three separate groups of homeopaths to prescribe for each group of children. This research discovered highly significant results (p=0.008). Her first study was published in *Pediatrics*, and her third study and summary of all three studies in *Pediatrics Infectious Disease Journal*.

A second series of three studies in the treatment of people with fibromyalgia was also systematically ignored, even when each of the below studies was conducted by different groups of researchers.

Iris Bell, MD, PhD, of the University of Arizona, published her study on 62 patients with fibromyalgia in the journal, *Rheumatology*, published by the British Society of Rheumatology (16). This randomized double-blind and placebo controlled trial found a substantially different decrease in patient pain and in overall quality of life (p=0.008) and a four-month follow-up reported significantly greater helpfulness of the homeopathic treatment versus the placebo (p=0.004).

Dr. Bell also measured EEG brain waves in patients given a homeopathic medicine as well as those given a placebo, and she also found objective evidence of differences in brain wave activity in those given a homeopathic medicine and those given a placebo (17). Therefore, this research found that homeopathic treatment provided a clinically relevant therapeutic benefit in addition to demonstrating observable physiologic changes as measured by EEG monitors.

In addition to the above study on fibromyalgia that was widely regarded as "high quality" (18), the *BMJ* published a double-blind, placebo controlled, with a crossover design on patients with fibromyalgia/fibrositis. This study used 30 patients, half of whom began treatment by taking a placebo for one month while the other half were prescribed a homeopathic medicine called Rhus toxicodendron 6C for the same period of time (19). Then, those patients who began by taking the placebo began taking the homeopathic medicine, and vice versa. The study found that whenever patients took the homeopathic medicine a significant improvement took place in all measured variables versus the experiences of the same group of patients when taking a placebo (p=0.005).

A third randomized controlled trial was conducted comparing "usual care" compared with usual medical care plus adjunctive care by a homeopath for patients with fibromyalgia syndrome (FMS) (20). Adjunctive care consisted of five in-depth interviews and individualized homeopathic medicines. The primary outcome measure was the difference in Fibromyalgia Impact Questionnaire (FIQ) total score at 22 weeks. ("Usual care" refers to one or more of the following: physiotherapy, aerobic exercise, analgesics, non-steroidal anti-inflammatory drugs, antidepressants.)

A total of 47 patients were recruited. Drop-out rate in the usual care group was higher than the homeopathic care group (8/24 vs 3/23). Adjusted for baseline, there was a significantly greater mean reduction in the FIQ total score (function) in the homeopathic care group than the usual care group (-7.62 vs 3.63). There were significantly greater reductions in the homeopathic care group in the McGill pain score, FIQ fatigue and tiredness upon waking scores. The study also found a small effect on pain score (0.21, 95% CI -1.42 to 1.84); but a large effect on function (0.81, 95% CI -8.17 to 9.79). There were no reported adverse events.

In contrast, the usual care group did not experience improvements in various measurements, and in fact, they experience some increases in the McGill pain score despite treatment prescribed by a rheumatologist.

Despite having THREE high-quality studies, two of which were published in leading medical journals, the Australian government's arbitrary guidelines for having 150 subjects in each trial lead the authors to totally ignore this body of scientific evidence.

A series of four high-quality studies in the treatment of respiratory allergies was ignored, even though one of the studies were published in the *British Medical Journal *(21) and two were published in the *Lancet*(22, 23). All of these studies were randomized, double-blind, and placebo-controlled. Further, independent researchers have consistently ranked these studies to be of the "highest quality" (24, 25).

A total of 259 patients were entered into these four high quality, randomized, double-blind, and placebo controlled trials. The results were so substantially significant (P=0.0007)(26) that the *British Medical Journal* commented on the results in an Editorial, asserting, *"It may be time to confront the conclusion that homeopathy and placebo differ.... This may be more plausible than the conclusion that their trials have produced serial false positive results." (27)*

Ultimately, those individuals and organizations that assert that there is "no good scientific evidence that homeopathy is effective" are simply proving that they discount studies which disagree with their a priori assumptions. A more balanced, objective review of the scientific literature cannot help but recognize that there is a body of scientific evidence that verifies the efficacy of homeopathic medicines.

The newest meta-analysis on homeopathic medicine chose to evaluate only those clinical trials that provided individualized treatment (28). *In reviewing the "highest quality studies," the researchers found that homeopathic patients were almost twice as likely to experience a therapeutic benefit as those given a placebo. Further, in reviewing a total of 22 clinical trials, the homeopathic patients experienced greater than 50% likelihood to have benefited from the homeopathic treatment than those given a placebo.*

Perhaps one of the strongest statements in this article was the confirmation that four of the five leading previous systematic reviews of homeopathic research also found a benefit from homeopathic treatment over that of placebo:
*"Five systematic reviews have examined the RCT research literature on homeopathy as a whole, including the broad spectrum of medical conditions that have been researched and by all forms of homeopathy: four of these 'global' systematic reviews reached the conclusion that, with important caveats, the homeopathic intervention probably differs from placebo."*
In addition to all of the above clinical research that consistently has shown benefits from homeopathic medicines for people with sleep problems, there is also a body of basic research that has shown up- and down-regulation of genetic expression from homeopathic medicines (29, 30, 31).*Who uses homeopathic medicines? *

History books that examine who used homeopathic medicines in the 19th century have consistently observed that homeopathic patients and users of homeopathic medicines tend to be considerably more educated than those who do not use homeopathic medicines. Surveys in the United States as well as conducted throughout the world in the 20th and 21st century have likewise observed this observation that users of homeopathic medicine are more educated than those who don't (33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43).

Thomas Jefferson, a Founding Father of the United States, maintained a certain strong point of view about the healthy balance between freedom of choice and about regulations that restrict this freedom. He asserted, "I know no safe depository of the ultimate power of society but the people themselves; and if we think them unable to exercise their control with a wholesome discretion, the remedy is not to remove it from them, but to educate their discretion."

In light of this thoroughly American point of view, I urge the FDA to work to provide the various freedoms that Americans have come to rely upon and utilize, along with an active effort to educate Americans so that each person can better make those private health decisions that are personal and important to them.

In 1990, a survey of American pharmacists discovered that 27% consider homeopathic medicines "useful," while only 18% consider them "useless." While over 75% of American pharmacists didn't know enough about homeopathy to have an opinion, this survey showed that of those who do know enough about it to have an opinion, many more consider homeopathic medicines beneficial.

A 2005 report from the National Center for Alternative and Complementary Medicine within NIH surveyed medical doctors and discovered that 5.9% of MDs have used homeopathy...and an impressive 27.9% "would use" homeopathy (44). A chapter in a prestigious medical textbook noted that a review of 25 surveys found that 9% of American physicians use homeopathic medicines in some way (45). A 2007 survey of osteopathic medical schools in the U.S. found that 48% of them teach homeopathy (46). These numbers suggest that a strong minority of physicians are interested in homeopathic medicine.

A 2000 survey of seniors in the US found that 5.8% have used homeopathy in the past year (47). The survey found that homeopathy had the highest positive response to treatment amongst all CAM treatments. The study found that 86% of those who used homeopathy experienced "a lot" or "quite a lot" of symptom relief. Other positive results included: guided imagery 84%, acupuncture 58%, and traditional Chinese medicine 57%.

This survey also found that 58% of respondents did not discuss their use of CAM treatments with their medical doctors. Among those aged 65-69, 46% reported CAM use compared with 31 % among the 80-84 age group, and with 23% for over 85 years of age. Of the elders who use CAM, 53% had a graduate degree.*What are consumer and health care provider attitudes towards human drug and biological products labeled as homeopathic?*

There is indeed confusion among consumers about what is and what isn't a homeopathic medicine, just as there is confusion about the differences between commonly used OTC drugs such as aspirin, acetaminophen, ibuprofen, and naproxen. However, the primary difference between homeopathy and these common OTC drugs is that the safety profile of homeopathic drugs is substantially greater.*What data sources can be identified or shared with FDA so that the Agency can better assess the risks and benefits of drug and biological products labeled as homeopathic?*

A useful resource for determining the "benefits" from homeopathic drugs can be obtained from an ebook that I've written and that I keep up-to-date as a leading resource for referencing and describing clinical research testing homeopathic medicines. This ebook is entitled "Evidence Based Homeopathic Family Medicine" and is available at www.homeopathic.com subscription (regular updates are made). Although PubMed and various other indexing systems have larger databases, they do not organize the body of clinical evidence according to disease names and do not provide analysis or critique of studies.

Determining the risks of homeopathic drugs can be determined, as it is now, by the Homeopathic Pharmacopeia Convention of the United States who analyze modern toxicological data to determine at which doses a homeopathic drug is deemed to be "basically safe."

If, however, a specific manufacturer wishes to encourage consumers to ingest their homeopathic medicine in a different form other than through the oral cavity, as was the case with Zicam which applied their medicine through the nose, it should be incumbent upon that manufacturer to provide safety evidence of their product through their means of ingestion.*Are the current enforcement policies under the CPG appropriate to protect and promote public health in light of the tremendous growth in the homeopathic drug market? Are there alternatives to the current enforcement policies of the CPG that would inform FDA's regulatory oversight of drugs labeled as homeopathic? If so, please explain.
*

First, the premise that there has been "tremendous growth" in the homeopathic drug market is simply not true, as we have reviewed above.

Whether the homeopathic marketplace is large, medium, or small, it is still worthy for the FDA to do what it can to improve safety. It must do so, however, on the basis of solid evidence.

The FDA should first direct the American Association of Poison Control Center Annual Report to provide more detailed information about which specific homeopathic drugs caused some type of "poisoning" and at which dose/potency. Without this information, the FDA would be regulating blindly.

Also, because there is now an active group of individuals and organizations in the U.S. that are working to restrict the sales and availability of homeopathic drugs, the Poison Control Center should develop guidelines to assess when a real poisoning has taken place and when a false report has been provided.*Are there areas of the current CPG that could benefit from additional clarity? If so, please explain.
*
Some homeopathic medicines in the U.S. marketplace mix homeopathic drugs with herbal ingredients. It would seem prudent for the CPG to make a clear statement about whether this is or isn't a legal practice.*Is there information regarding the regulation of homeopathic products in other countries that could inform FDA's thinking in this area?*

At present, the FDA allows certain plants, minerals, animal, chemical, and select other ingredients to be legally recognized as a "homeopathic drug" if evidence of their usage was highlighted in one of the handful of homeopathic textbooks that was published in the late 1800s and early 1900s. The FDA differentiates OTC homeopathic drugs from Rx homeopathic drugs, the FDA and defines "OTC homeopathic drugs" as those that have a potential OTC indication AND when the specific medicine is basically considered safe in a specific dose. This latter determination of safety was made in light of modern toxicology. Therefore, certain herbs like belladonna would only be deemed to be a homeopathic OTC drug in the 3X but would be Rx in the 1X and 2X dosage. Also, snake venoms, such as Lachesis, is deemed to be a homeopathic OTC drug in the 8th but is deemed to be an Rx in all lower potencies. These determinations are drawn from the toxicological literature for consumer protection. It seems prudent to maintain these high standards of safety.

In Europe, the European Parliament has added an additional definition of what constitutes a homeopathic drug, as distinct from an herbal preparation or a conventional drug, by"there is a sufficient degree of dilution to guarantee the safety of the medicinal product; in particular, the medicinal product may not contain either more than one part per 10 000 of the mother tincture or more than 1/100th of the smallest dose used in allopathy with regard to active substances whose presence in an allopathic medicinal product results in the obligation to submit a doctor's prescription." (48)

*A large majority of human drug products labeled as homeopathic are marketed as OTC drugs. These products are available for a wide variety of indications, and many of these indications have never been considered for OTC use under a formal regulatory process. What would be an appropriate regulatory process for evaluating such indications for OTC use?*

At present, determination for when a drug is considered an "OTC drug" is if the indication for usage doesn't require a medical diagnosis, when the condition is self-limiting, and when the dosage is basically safe. These guidelines seem appropriate for yesterday, today, and tomorrow.*Given the wide range of indications on drug products labeled as homeopathic and available OTC, what processes do companies currently use to evaluate whether such products, including their indications for use, are appropriate for marketing as an OTC drug? Do consumers and health care providers have adequate information to make informed decisions about drug products labeled as homeopathic? If not, what information, including, for example, information in labeling, would allow consumers and health care providers to be better informed about products labeled as homeopathic?*

I am the co-author of a book, originally published in 1984, that has been the most popular guidebook to using homeopathic medicines for families (49). One of the reasons for its popularity is that it not only provided helpful advice on how to use homeopathic medicines, but also because it provided medically competent guidelines on when adults and children should consider getting medical care and provided specific recommendations as to when people should seek medical care "immediately,""within 24 hours," or simply "get it checked out soon," let alone the real and frequent side effects even when the seemingly "right" medicine is prescribed.

Because it is so important for consumers to have clear guidelines as to when they should consider getting medical attention, it would seem to be important that the National Institutes of Health develop such clear guidelines. These guidelines would not only educate individuals as to when medical attention may be necessary, but it will also educate people when it is necessarily essential to get medical care.

Some presenters at the FDA hearing on April 20-21, 2015, suggested that homeopathic medicine be listed in non-homeopathic dosage form, ie, milligrams. Such standardization would create confusion rather than clarity. Because the experience of 200+ years of experience with homeopathic medicines is that the medicines act deeper, longer, and require fewer doses when they undergo a higher number of 1:10 or 1:100 dilutions, with vigorous succession in-between each dilution, the consumer would be incorrectly informed that the lower potency medicines would require fewer repeated doses and the higher potency medicines would require an increased number of doses.*Dana Ullman, MPH, CCH*, is America's leading spokesperson for homeopathy and is the founder of www.homeopathic.com . He is the author of 10 books, including his bestseller, Everybody's Guide to Homeopathic Medicines. His most recent book is, The Homeopathic Revolution: Why Famous People and Cultural Heroes Choose Homeopathy (the Foreword to this book was written by Dr. Peter Fisher, the Physician to Her Majesty Queen Elizabeth II). Dana lives, practices, and writes from Berkeley, California. He sees patients from all over the world via phone and Skype and in his Berkeley office.
REFERENCES:

(1) http://www.fda.gov/Drugs/NewsEvents/ucm430539.htm
(2) World Health Organization, Safety Issues in the Preparation of Homeopathic Medicines, 2009. http://www.who.int/medicines/areas/traditional/Homeopathy.pdfhttp://www.who.int/medicines/areas/traditional/Homeopathy.pdf
(3) Gawande, Atul. Overkill: An avalanche of unnecessary medical care is harming patients physically and financially. What can we do about it? New Yorker, May 11, 2015: http://www.newyorker.com/magazine/2015/05/11/overkill-atul-gawande
(4) Piolot M, Fagot JP, Rivière S, Fagot-Campagna A, Debeugny G, Couzigou P, Alla F. Homeopathy in France in 2011-2012 according to reimbursements in the French national health insurance database (SNIIRAM). Fam Pract. 2015 Apr 28. http://www.ncbi.nlm.nih.gov/pubmed/25921648
(5) https://en.wikipedia.org/wiki/World_Health_Organization_ranking_of_health_systems_in_2000
(6) Tuffs A. German doctors and politicians disagree on reimbursement for homoeopathy. BMJ 2010;341:33902. http://www.bmj.com/content/341/bmj.c3902
(7) Annuario Scienza e Societa 2012, edizioni Il Mulino Ottava edizione, a cura di F. Neresini e G. Pellegrini (Translated as: YEARBOOK OF SCIENCE AND SOCIETY) http://www.observa.it/pubblicazioni_view.aspx?ID=1233&LAN=ITA
(8) Prasad R. Homoeopathy booming in India. Lancet, 370:November 17, 2007,1679-80. http://www.ncbi.nlm.nih.gov/pubmed/18035598
(9) Chikramane PS, Kalita D, Suresh AK, Kane SG, Bellare JR. Why Extreme Dilutions Reach Non-zero Asymptotes: A Nanoparticulate Hypothesis Based on Froth Flotation. Langmuir. 2012 Nov 1. http://www.ncbi.nlm.nih.gov/pubmed/23083226
(10) Market Report: Herbal and Homeo, OTC Market Report Update USA, July, 1994: 217-28.
(11) Furmer, Melinda, Homeopathic Remedies Thrive in the Mainstream, Los Angeles Times March 22, 2004. http://www.religionnewsblog.com/6521/homeopathic-remedies-thrive-in-mainstream
(12) Australian Government National Health and Medical Research Council Statement on Homeopathy and NHMRC Information Paper - Evidence on the effectiveness of homeopathy for treating health conditions, March 2015, p. 35: "For the purposes of the homeopathy overview, studies were considered to be of sufficient size where N>150 (i.e. those studies categorised as 'medium' sized or larger), as the outcomes were generally continuous outcomes." http://www.nhmrc.gov.au/guidelines-publications/cam02
(13) What conclusions have Clinical Evidence drawn about what works, what doesn't based on randomised controlled trial evidence? BMJ, 2015. http://clinicalevidence.bmj.com/x/set/static/cms/efficacy-categorisations.html
(14) Nuts, bolts, and tiny little screws: how Clinical Evidence works. BMJ, 2015 http://clinicalevidence.bmj.com/x/set/static/cms/nuts-and-bolts.html
(15) http://www.bmj.com/content/346/bmj.f2304
(16) Bell, IR, Lewis, DA, Brooks, DJ, Schwartz, GE, Leis, SE, Walsh, BT, and Baldwin, DM, Improved Clinical Status in Fibromyalgia Patients Treated with Individualized Homeopathic Remedies Versus Placebo, Rheumatology, January 20, 2004:1111-7.
(17) Bell IR, Lewis Ii DA, Lewis SE, Schwartz GE, Brooks AJ, Scott A, Baldwin CM. EEG Alpha Sensitization in Individualized Homeopathic Treatment of Fibromyalgia, Int J Neurosci. 2004;114(9):1195-1220.
(18) Mathie RT, Lloyd SM, Legg LA, Clausen J, Moss S, Davidson JR, Ford I. Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis. Systematic Reviews 2014; 3:142. doi:10.1186/2046-4053-3-142. http://www.systematicreviewsjournal.com/content/3/1/142
(19) Fisher P, Greenwood A, Huskisson EC, et al., "Effect of Homoeopathic Treatment on Fibrositis (Primary Fibromyalgia)," BMJ, 299(August 5, 1989):365-6.
(20) Relton C, Smith C, Raw J, Walters C, Adebajo AO, Thomas KJ, Young TA.
Healthcare provided by a homeopath as an adjunct to usual care for Fibromyalgia (FMS): results of a pilot Randomised Controlled Trial. Homeopathy. 2009 Apr;98(2):77-82.
(21) Taylor, MA, Reilly, D, Llewellyn-Jones, RH, et al., Randomised controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial Series, BMJ, August 19, 2000, 321:471-476.
(22) Reilly, D, "Is homoeopathy a placebo response? controlled trial of homoeopathic potency, with pollen in hayfever as model," Lancet, October 18, 1986, ii: 881-6.
(23) Reilly, D, Taylor, M, Beattie, N, et al., "Is evidence for homoeopathy reproducible?" Lancet, December 10, 1994, 344:1601-6.
(24) Linde, K., Clausius, N., Ramirez, G., et al., "Are the Clinical Effects of Homoeopathy Placebo Effects? A Meta-analysis of Placebo-Controlled Trials," Lancet, September 20, 1997, 350:834-843.
(25) Kleijnen J, Knipschild P, ter Riet G. Clinical trials of homoeopathy. BMJ. 1991 Feb 9;302(6772):316-23.
(26) Taylor, MA, Reilly, D, Llewellyn-Jones, RH, et al., Randomised controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial Series, BMJ, August 19, 2000, 321:471-476.
(27) Homoeopathic dilutions may be better than placebo. BMJ 2000;321. http://bmj.com/cgi/content/full/321/7259/0/b
(28) Mathie RT, Lloyd SM, Legg LA, Clausen J, Moss S, Davidson JR, Ford I. Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis. Systematic Reviews 2014; 3:142. doi:10.1186/2046-4053-3-142. http://www.systematicreviewsjournal.com/content/3/1/142
(29) Marzotto M, Olioso D, Bellavite P. Gene expression and highly diluted molecules. Front Pharmacol. 2014; 5: 237. 2014 November 12. doi: 10.3389/fphar.2014.00237
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228849/
(30) Khuda-Bukhsh, AR. Current trends in high dilution research with particular reference to gene regulatory hypothesis. The Nucleus. 57:1,18 March 2014:3-17. http://link.springer.com/article/10.1007%2Fs13237-014-0105-0#page-1
(31) Bellavite P, Signorini A, Marzotto M, Moratti E, Bonafini C, Olioso D. Cell sensitivity, non-linearity and inverse effects. Homeopathy, 104, 2(April 2015):139-160. http://www.sciencedirect.com/science/article/pii/S1475491615000053
(32) Rothstein, W. Physicians in the Nineteenth Century. Baltimore: Johns Hopkins University Press, 1972.
(33) Avina RL, Schneiderman LJ, Why Patients Choose Homeopathy, Western Journal of Medicine. 128,4 April 1978, 366-369.
(33) Du Y, Knopf H. Paediatric homoeopathy in Germany: results of the German health interview and examination survey for children and adolescents (KiGGS). Pharmacoepidemiol Drug Saf. 2009 Feb 23.
(34) Spigelblatt Linda, Laîné-Ammara Gisèle, Pless I. Barry, et al. The Use of Alternative Medicine by Children. Pediatrics 1994; 94:6 811-814.
(35) Hensel M, Zoz M, Ho AD. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer. 2008 May 6.
(36) Schwarz S, Knorr C, Geiger H, Flachenecker P. Complementary and alternative medicine for multiple sclerosis. Mult Scler. 2008 Sep;14(8):1113-9.
(37) Marian F, Joost K, Saini KD, et al Patient satisfaction and side effects in primary care: an observational study comparing homeopathy and conventional medicine. BMC Comp Alt Med 2008, 8:52. doi:10.1186/1472-6882-8-52.
(38) Clerici CA, Veneroni L, Giacon B, et al., Complementary and alternative medical therapies used by children with cancer treated at an Italian pediatric oncology unit. Pediatric Blood Cancer. June 2009. doi 10.1002/pbc.22093.
(39) Gomez-Martinez R, Tlacuilo-Parra A, Garibaldi-Covarrubias R. Use of complementary and alternative medicine in children with cancer in Occidental, Mexico. Pediatr Blood Cancer 2007;49:820-823.
(40) Gozum S, Arikan D, Bu¨yu¨kavci M. Complementary and alternative medicine use in pediatric oncology patients in eastern Turkey. Cancer Nurs 2007;30:38-44.
(41) Nathanson I, Sandler E, Ramırez-Garnica G, et al. Factors influencing complementary and alternative medicine use in a multisite pediatric oncology practice. J Pediatr Hematol Oncol 2007;29:705-708.
(42) D'Inca R, Garribba AT, Vettorato MG, Martin A, Martines D, Di Leo V, Buda A, Sturniolo GC, Use of alternative and complementary therapies by inflammatory bowel disease patients in an Italian tertiary referral centre, Dig Liver Dis. 2007 Apr 10.
(43) Clines, F. "With Medicine Itself Sick, Russians Turn to Herbs," New York Times, December 31, 1990
(44) National Center for Alternative and Complementary Medicine, Percentage of Physicians Who Have Used or Who Would Use CAM Practices by Specialty (n-783), 2005.
(45) Jonas, W.B., Chez, R.A. Complementary & alternative medicine. In Current Diagnosis & Treatment in Family Medicine. South-Paul, JE, Matheny, SC and Lewis, EL (Eds). New York: McGraw-Hill 2007; pp.549-557.
(46) Dale W. Saxon, PhD; Godfrey Tunnicliff, PhD; James J. Brokaw, PhD, MPH; Beat U. Raess, PhD Status of Complementary and Alternative Medicine in the Osteopathic Medical School Curriculum. JAOA, 104,3: March 2004, 121-126.
(47) Astin JA, Pelletier KR, Marie A, and Haskell WL. Complementary and Alternative Medicine Use Among Elderly Persons: One-Year Analysis of a Blue Shield Medicare Supplement, J Gerontol A Biol Sci Med Sci (2000) 55 (1): M4-M9. doi: 10.1093/gerona/55.1.M4 http://biomedgerontology.oxfordjournals.org/content/55/1/M4.long
(48) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 27)
(49) Cummings S and Ullman D. Everybody's guide to homeopathic medicines. New York: Jeremy Tarcher/Putnam. 2004.

-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. Reported by Huffington Post 1 hour ago.

Kaiser: health insurance deductibles rise sharply

$
0
0
Sharply higher health insurance deductibles have outpaced moderating increases in health insurance premiums for workers who have employer-provided health insurance, a new survey found. Since 2010, the share of workers with health plan deductibles and the size of those deductibles have increased sharply, according to a health benefits survey conducted by the Kaiser Family Foundation/ Health Research & Educational Trust, based in Menlo Park, Calif. Combined, these trends have resulted in a 67 percent… Reported by bizjournals 1 hour ago.

CBO: Individual Mandate Repeal Would Undo Historic Health Coverage Gains

$
0
0
As part of budget reconciliation legislation that may move in coming weeks, House Republican leaders are likely to include a repeal of health reform's requirement, known as the individual mandate, that most individuals have insurance or pay a penalty.  That would reverse much of the historic progress the nation has made -- and will continue to make -- in reducing the ranks of the uninsured.The uninsured rate fell sharply by 2.9 percentage points and the number of uninsured Americans dropped by 8.8 million between 2013 and 2014, according to new Census Bureau data.  These are by far the largest single-year reductions on record in data back to 1987, driven primarily by health reform's major coverage expansions that first took effect last year.  Moreover, other government and private surveys find further substantial reductions in the share and number of uninsured in 2015. Repealing the individual mandate would undo much of that progress.  The Congressional Budget Office (CBO) estimates that repealing the individual mandate would:

· *Increase the number of uninsured by 14 million in 2025, relative to current law*.  Without the individual mandate, many fewer people would enroll in job-based coverage, subsidized private coverage through health reform's marketplaces, Medicaid, the Children's Health Insurance Program, or other sources of coverage.  CBO expects that in 2025, there would be nearly 52 percent more people (41 million) without health insurance than under current law (27 million).· *Raise premiums by 20 percent for coverage purchased through the individual market inside and outside the marketplaces in all years between 2017 and 2025.*  Without the individual mandate, healthier people would be those most likely to drop or otherwise go without coverage.  Losing healthy people from the risk pool would push up individual market premiums for everyone else by making those still enrolled sicker and costlier to cover, on average.  Higher premiums, in turn, would push more healthy people out of the pool over time, driving up premiums still further.

These CBO estimates are consistent with its prior estimates and also with recently updated estimates from RAND, which projects that repealing the individual mandate would increase the number of uninsured by 12.3 million and raise individual market premiums in 2017.  Earlier analyses from the Urban Institute and the Lewin Group produced similar results.
This post originally appeared on Off the Charts, the Center on Budget and Policy Priorities' blog.

-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. Reported by Huffington Post 1 hour ago.

10 Open Enrollment Mistakes to Avoid

$
0
0
Fall signals a change in the weather and for many workers, the beginning of open enrollment -- the annual benefits sign-up period for the coming year.

Open enrollment periods usually run for a few weeks between September and November in most workplaces. This yearly event, usually administered by the human resources department at most employers, allows you and your fellow employees to review past benefits choices, ask questions and make selections on health and related insurance products, retirement plans and other elective perks and discounts including transportation credits and tuition reimbursement.

The reality is that many employees make decisions too quickly or forget to address key personal needs in their selections. In fact, a recent survey by insurer Aflac says that 90 percent of Americans choose the same benefits year after year and that 42 percent forego up to $750 annually by making choices that don't fit their needs.

However, rushed or poor choices in insurance, retirement or other workplace-based benefits are part of a bigger story. Open enrollment is the smaller companion to self-directed savings and investment choices you should be making outside the workplace. Many employers are looking to shrink or discontinue the retirement and health benefits they offer, making it necessary for employees to focus on personal planning more than ever.

As open enrollment approaches at your workplace, here are some mistakes you might want to avoid:
1. *Thinking open enrollment is the only financial planning you need to do*. Your company may offer excellent retirement, healthcare, education and insurance benefits now. But given that the average worker tenure at U.S. companies is only 4.6 years, the biggest open enrollment mistake might be a lack of independent financial planning and personal savings and investment. Whether or not you work with a qualified financial advisor, most Americans need to save and invest independently from employer-sponsored plans. Qualified advisors can evaluate individual financial, lifestyle and tax circumstances and help clients select employer-based investments and benefits to complement what they're doing on their own.3. *Failing to read and prepare for open enrollment*. Open enrollment dates can creep up on you. If your open enrollment period occurs at the same time every year, mark your calendar a few weeks ahead so you can start thinking and getting advice on benefits for the coming year. Choosing benefits is an important financial decision; make the right amount of time to review options.5. *Forgetting to coordinate benefits with your spouse or partner*. Two-income families -- particularly those with kids -- might schedule a bit more time to compare benefits they're entitled to separately or together. While the Patient Protection and Affordable Care Act (ACA) lets parents keep children on their health plans until age 26, more employers are instituting "spousal surcharges" or excluding spousal coverage altogether if spouses already have access to employer health insurance. According to Towers Watson, by 2017, 63 percent of employer plans will block spouses who have their own employer coverage or add surcharges that can range from $500 to $3,000 a year.7. *Ignoring your state's Health Insurance Marketplace*. Circumstances change, so if you lose a job or find it too expensive to stay on your spouse or partner's health plan, familiarize yourself with your state's ACA-mandated health insurance marketplace as one of your potential health coverage options.9. *Forgetting to evaluate how big life events might affect your benefits*. Major life events can become financial events very quickly. Pay raises or cuts, a spouse/partner getting or losing a job, marriage, divorce, serious illness or starting a family require a benefits checkup, preferably well in advance of open enrollment. Think through every potential situation you and your family might face and ask questions about how those changes might affect your benefit selections.11. *Ignoring flexible spending accounts (FSAs) and health savings accounts (HSAs)*. FSAs are workplace-based accounts that allow you to set aside money on a pre-tax basis to help you pay for healthcare and dependent care expenses during the calendar year. HSAs, if you qualify, also allow you to set aside pre-tax dollars in a qualified investment or savings account for long-and-short term medical expenses not covered by insurance. HSAs don't require you to spend out those funds every year. Your workplace benefits counselor, qualified financial advisor and Internal Revenue Service Publication 969 can outline eligibility, types of accounts, contribution limits and tax issues associated with these choices.13. *Leaving retirement selections unchanged*. As the Aflac data indicates, many people don't change their investment choices in self-directed retirement plans for years. Many also make uninformed choices that are too aggressive or conservative for their needs. Reviewing employer-based retirement options annually against personal savings and investments is essential.15. *Brushing off wellness options*. Many employers pay for exercise, cholesterol screenings, weight loss, smoking cessation, immunizations or related benefits that can make you healthier and possibly lower your healthcare premiums.17. *Bypassing transportation breaks*. If you drive or take public or company-sponsored transportation to and from work, you may qualify for specific discounts or tax deductions. Check IRS Publication 15-B for the latest information on such programs and how to use them most efficiently.19. *Forgetting education benefits*. If an employer is willing to train you to advance in your career, don't ignore the opportunity, but keep an eye on any potential tax liability for those benefits. Also, don't forget employer-sponsored grant or scholarship awards for you or your kids -- that can be free money.
*Bottom line*: Open enrollment is much more than a rush to fill out insurance forms every year. Do your homework or consult a professional before making these important choices for health, retirement and other key employee benefits that impact your overall budget.

Nathaniel Sillin directs Visa's financial education programs. To follow Practical Money Skills on Twitter: www.twitter.com/PracticalMoney

-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. Reported by Huffington Post 35 minutes ago.

Metro Orlando ranks in top 50 for most uninsured people

$
0
0
Despite a rise in the number of people with health insurance, metro Orlando still has one of the most uninsured populations in the U.S, according to census data. As of 2014, 17.6 percent of metro Orlando's population was uninsured. With a population of about 2.3 million, that's roughly 405,000 people with no health coverage. That's a 3 percent improvement from 2013, when about 20.5 percent of the population was uninsured — meaning 460,444 people lacked health insurance out of a population of 2.25… Reported by bizjournals 30 minutes ago.

Uninsured rate in Washington state, Puget Sound region drops

$
0
0
The number of people in Washington state without health coverage is dropping. The U.S. Census just released data in the Health Insurance Coverage in the United States: 2014 report, showing how much the uninsured rate has dropped here and across the country since federal health exchange and state health exchanges went live post-Affordable Care Act. From 2013 to 2014, the rate of uninsured people in Washington state dropped from 14 percent to 9.2 percent. In the Seattle metro area, that drop was… Reported by bizjournals 1 day ago.

Clinton Plan Aims to Limit Cost of Health Insurance

$
0
0
Hillary Clinton released more proposals for limiting what people with insurance pay for their health care, amid an effort to show she is seeking to improve the 2010 federal health law with cost provisions. Reported by Wall Street Journal 20 hours ago.
Viewing all 22794 articles
Browse latest View live




Latest Images